HERA

NCT00045032 📎

Regimen

Experimental
Trastuzumab 6 mg/kg IV every 3 weeks for 1 year (or 2 years in the three-arm comparison), after completion of chemotherapy.
Control
Observation (no trastuzumab).

Population

HER2-positive early breast cancer, node-positive or high-risk node-negative, after completion of primary chemotherapy (with or without radiotherapy).

Key finding

HERA established 1 year of adjuvant trastuzumab after chemotherapy as standard of care in HER2-positive early breast cancer. Long-term follow-up (2017) confirmed durable benefit and showed 2 years was not superior to 1 year. Anchor trial for NCCN category 1 adjuvant trastuzumab recommendation.

Source: PMID 16236737

Timeline

  • Publication: 2005 Oct 20

Guideline citations

  • NCCN BREAST